In 2006, Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by the Medical House’s GH1. The Medical House has never been able to supply Biopartners with the GH1 devices needed to perform this clinical study. Therefore, Biopartners terminated the collaboration.
Jean-Noel Treilles, CEO of Biopartners, said: “Having received EMEA approval in April 2006, we had planned to launch Valtropin at the end of that year. However, with the GH1 device not functioning correctly, we have had to end our agreement with the Medical House in order to seek a suitable and robust alternative delivery system.”